TQB3804

TQB3804 is an orally administered, fourth-generation small molecule inhibitor that selectively targets mutant forms of the epidermal growth factor receptor (EGFR), including the C797S mutation. It is designed to overcome resistance to third-generation EGFR inhibitors such as osimertinib by inhibiting EGFR-mediated signaling pathways in tumor cells harboring these mutations. TQB3804 has demonstrated potent inhibitory activity against a range of EGFR mutations (including d746-750/T790M/C797S and L858R/T790M/C797S) in preclinical models and is being developed primarily for the treatment of non-small cell lung cancer (NSCLC) and other advanced solid tumors. The drug was initially developed by Chia Tai Tianqing Pharmaceutical Group[1][2][3][4][5][6][7][8].